EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

被引：0
|
作者：
Dinh, M. [1 ]
Pithavala, Y. [1 ]
Chen, J. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-053
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [11] Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
    不详
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S402 - S402
  • [12] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [13] Evaluation of Texture Analysis Parameters in EGFR Mutated or ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
    Bluthgen, Maria V.
    Caramella, Caroline
    Rosellini, Silvia
    Leduc, Charlotte
    Facchinetti, Francesco
    Haspinger, Eva
    Ferte, Charles
    Michiels, Stefan
    Soria, Jean C.
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S703 - S703
  • [14] Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.
    Bearz, Alessandra
    Martini, Jean-Francois
    Jassem, Jacek
    Kim, Sang-We
    Chang, Gee-Chen
    Shaw, Alice
    Shepard, Deborah
    Dall'O', Elisa
    Polli, Anna
    Thurm, Holger
    Zalcman, Gerard
    Garcia Campelo, Maria Rosario
    Penkov, Konstantin
    Hayashi, Hidetoshi
    Solomon, Benjamin J.
    CANCER RESEARCH, 2021, 81 (13)
  • [15] Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer
    Lu, Shun
    Zhou, Qing
    Liu, Xiaoqing
    Du, Yingying
    Fan, Yun
    Cheng, Ying
    He, Shan
    Zhao, Huadong
    Li, Heyan
    Wu, Yi-Long
    CLINICAL LUNG CANCER, 2024, 25 (07)
  • [16] A POST-HOC ANALYSIS OF POTENTIAL ETHNIC DIFFERENCES IN LORLATINIB PHARMACOKINETICS (PK) IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).
    Albanez, J.
    Pithavala, Y.
    Chen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S6 - S6
  • [17] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
    Shaohua Cui
    Yizhuo Zhao
    Aiqin Gu
    Xiaoxiao Ge
    Yanyan Song
    Wei Zhang
    Yuqing Lou
    Lili Dong
    Baohui Han
    Liyan Jiang
    Medical Oncology, 2015, 32
  • [18] New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer
    Pasquier, Corentin
    Basse, Clemence
    BULLETIN DU CANCER, 2022, 109 (09) : 877 - 878
  • [19] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    MEDICAL ONCOLOGY, 2015, 32 (06)
  • [20] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
    Lin, Jessica J.
    Gainor, Justin F.
    LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
12345